BioCentury | Jan 14, 2013
Clinical News

UMK-121: Phase I start

...In the "coming months," Proteonomix and the University of Medicine and Dentistry of New Jersey will...
...terminated a November 2011 deal to conduct Phase I testing for UMK-121 in the indication. Proteonomix...
...the deal for "business reasons," but declined to disclose details (see BioCentury, Dec. 5, 2011). Proteonomix...
BioCentury | Aug 27, 2012
Company News

Proteonomix Inc. deal

...up to $950,000 plus 50,000 Proteonomix common shares, as well as 3% royalty on sales. Proteonomix...
...terminated a November 2011 deal to conduct Phase I testing for UMK-121 in the indication. Proteonomix...
...the deal for "business reasons," but declined to disclose details (see BioCentury, Dec. 5, 2011). Proteonomix...
BioCentury | Jun 11, 2012
Finance

Unwinding Rodman

...and my intention is to continue working with them." Michael Cohen, CEO of proteomics play Proteonomix...
...Wash. Direct Markets Holdings Corp. (NASDAQ:MKTS), New York, N.Y. Novelos Therapeutics Inc. (OTCQX:NVLT), Newton, Mass. Proteonomix...
BioCentury | Mar 26, 2012
Financial News

Proteonomix Inc. completes private placement of convertible preferred stock and warrants

Proteonomix Inc. (OTCBB:PROT), Mountainside, N.J. Business: Proteomics, Gene/Cell therapy Date completed: 3/19/12 Type: Private placement of convertible preferred stock and warrants Raised: $3.8 million Shares: 3,804 Price: $1,000 Placement agent: Rodman Shares outstanding prior: 7.4...
BioCentury | Mar 12, 2012
Financial News

Proteonomix proposes private placement of convertible preferred stock and warrants

Proteonomix Inc. (OTCBB:PROT), Mountainside, N.J. Business: Proteomics, Gene/Cell therapy Date announced: 3/6/12 Type: Private placement of convertible preferred stock and warrants To be raised: $3.8 million Shares: TBD Price prior: $5 Placement agent: Rodman Investors:...
BioCentury | Mar 5, 2012
Clinical News

UMK-121: Phase I started

...will contribute $105,000 (see BioCentury, Dec. 5, 2011). Details of the trial were not disclosed. Proteonomix...
...from the not-for-profit Cohen McNiece Foundation Inc. (Coral Gables, Fla.) (see BioCentury, March 21, 2011). Proteonomix...
BioCentury | Feb 13, 2012
Company News

Proteonomix management update

Proteonomix Inc. (OTCBB:PROT), Mountainside, N.J. Business: Proteomics, Gene/Cell therapy Hired: Steven Byle, a director, as chief technology officer, formerly chief technology officer and VP of technology at Dockwise Ltd. WIR Staff...
BioCentury | Dec 5, 2011
Company News

Proteonomix Inc., University of Miami deal

...The university will pay expenses associated with the study and the company will contribute $105,000. Proteonomix...
...cells from the not-for-profit Cohen McNiece Foundation Inc. (Coral Gables, Fla.) (see BioCentury, March 21). Proteonomix...
BioCentury | Jun 27, 2011
Company News

Proteonomix dermatology, cardiovascular, gene/cell therapy news

...three-month operating loss of $280,097. Proteonomix Inc. (OTCBB:PROT), Mountainside, N.J. Business: Dermatology, Cardiovascular, Gene/Cell therapy Proteonomix...
BioCentury | Mar 21, 2011
Company News

Proteonomix, Cohen McNiece Foundation Inc. deal

...The not-for-profit foundation granted Proteonomix exclusive, worldwide rights to its UMK-121 technology covering the mobilization of...
...exclusive, worldwide rights to its UMK-121 technology covering the mobilization of bone marrow stem cells. Proteonomix...
...eligible for milestones, plus 3% royalties. Further terms were not disclosed (see BioCentury, March 14). Proteonomix...
Items per page:
1 - 10 of 20
BioCentury | Jan 14, 2013
Clinical News

UMK-121: Phase I start

...In the "coming months," Proteonomix and the University of Medicine and Dentistry of New Jersey will...
...terminated a November 2011 deal to conduct Phase I testing for UMK-121 in the indication. Proteonomix...
...the deal for "business reasons," but declined to disclose details (see BioCentury, Dec. 5, 2011). Proteonomix...
BioCentury | Aug 27, 2012
Company News

Proteonomix Inc. deal

...up to $950,000 plus 50,000 Proteonomix common shares, as well as 3% royalty on sales. Proteonomix...
...terminated a November 2011 deal to conduct Phase I testing for UMK-121 in the indication. Proteonomix...
...the deal for "business reasons," but declined to disclose details (see BioCentury, Dec. 5, 2011). Proteonomix...
BioCentury | Jun 11, 2012
Finance

Unwinding Rodman

...and my intention is to continue working with them." Michael Cohen, CEO of proteomics play Proteonomix...
...Wash. Direct Markets Holdings Corp. (NASDAQ:MKTS), New York, N.Y. Novelos Therapeutics Inc. (OTCQX:NVLT), Newton, Mass. Proteonomix...
BioCentury | Mar 26, 2012
Financial News

Proteonomix Inc. completes private placement of convertible preferred stock and warrants

Proteonomix Inc. (OTCBB:PROT), Mountainside, N.J. Business: Proteomics, Gene/Cell therapy Date completed: 3/19/12 Type: Private placement of convertible preferred stock and warrants Raised: $3.8 million Shares: 3,804 Price: $1,000 Placement agent: Rodman Shares outstanding prior: 7.4...
BioCentury | Mar 12, 2012
Financial News

Proteonomix proposes private placement of convertible preferred stock and warrants

Proteonomix Inc. (OTCBB:PROT), Mountainside, N.J. Business: Proteomics, Gene/Cell therapy Date announced: 3/6/12 Type: Private placement of convertible preferred stock and warrants To be raised: $3.8 million Shares: TBD Price prior: $5 Placement agent: Rodman Investors:...
BioCentury | Mar 5, 2012
Clinical News

UMK-121: Phase I started

...will contribute $105,000 (see BioCentury, Dec. 5, 2011). Details of the trial were not disclosed. Proteonomix...
...from the not-for-profit Cohen McNiece Foundation Inc. (Coral Gables, Fla.) (see BioCentury, March 21, 2011). Proteonomix...
BioCentury | Feb 13, 2012
Company News

Proteonomix management update

Proteonomix Inc. (OTCBB:PROT), Mountainside, N.J. Business: Proteomics, Gene/Cell therapy Hired: Steven Byle, a director, as chief technology officer, formerly chief technology officer and VP of technology at Dockwise Ltd. WIR Staff...
BioCentury | Dec 5, 2011
Company News

Proteonomix Inc., University of Miami deal

...The university will pay expenses associated with the study and the company will contribute $105,000. Proteonomix...
...cells from the not-for-profit Cohen McNiece Foundation Inc. (Coral Gables, Fla.) (see BioCentury, March 21). Proteonomix...
BioCentury | Jun 27, 2011
Company News

Proteonomix dermatology, cardiovascular, gene/cell therapy news

...three-month operating loss of $280,097. Proteonomix Inc. (OTCBB:PROT), Mountainside, N.J. Business: Dermatology, Cardiovascular, Gene/Cell therapy Proteonomix...
BioCentury | Mar 21, 2011
Company News

Proteonomix, Cohen McNiece Foundation Inc. deal

...The not-for-profit foundation granted Proteonomix exclusive, worldwide rights to its UMK-121 technology covering the mobilization of...
...exclusive, worldwide rights to its UMK-121 technology covering the mobilization of bone marrow stem cells. Proteonomix...
...eligible for milestones, plus 3% royalties. Further terms were not disclosed (see BioCentury, March 14). Proteonomix...
Items per page:
1 - 10 of 20